Antimicrobial Resistance Diagnostics Market (By Technology: Microbiology Culture, Immunoassay, PCR, NGS; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global antimicrobial resistance diagnostics market was surpassed at USD 3.5 billion in 2021 and is expected to hit around USD 7.3 billion by 2030, growing at a CAGR of 8.51% from 2022 to 2030.

Antimicrobial Resistance Diagnostics Market Size 2021 to 2030

The growth of the antimicrobial resistance diagnostics market is attributed to the increased risk of developing drug-resistant bacterial infections, the introduction of novel technologies, and increasing government initiatives to diagnose & reduce AMR infections. To address the global health challenge of AMR, government bodies such as the U.S. FDA support the development of next-generation sequencing-based diagnostic tests to identify the right pathogen to help healthcare providers to treat infections more accurately.

Increasing adoption of point of care and rapid testing for drug-resistant microbial infections is expected to fuel the market growth in the forecast period. PCR technology-based POC tests are expected to control the progression of hospital-acquired infections (HAIs) in healthcare facilities. Moreover, key market players such as Abbott, F. Hoffmann-La Roche Ltd, and others have a strong product portfolio of rapid diagnostic tests for multiple drug-resistant infections. Moreover, increasing involvement of government and non-government bodies such as the AMR Industry Alliance is helping to build strategies to support diagnostic development to reduce antimicrobial resistance.

The AMR diagnostics market is segmented based on technology, pathogen, and end-user. Among the technology segment, the polymerase chain reaction segment held the largest share in 2021 and is expected to maintain its dominance through the forecast period. High penetration of PCR technology and advancements in the technology has increased the segment share. Moreover, the high adoption rate of PCR tests for HAIs such as c. difficile and MRSA is further driving segment growth. However, the rapid & point of care segment is anticipated to grow at the fastest rate in the forecast period.

North America is the largest market for antimicrobial resistance diagnostics. The high risk of developing AMR infections, developed healthcare infrastructure, favorable healthcare policies, and presence of key market players in the region have increased the market share. According to an article published by CDC in August 2022, in the U.S., around 2.8 million people are diagnosed with antibiotic-resistant infections each year. MRSA and c.difficile are major prevalent infections reported in the U.S. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The growth of the region can be attributed to the increasing adoption of novel diagnostic techniques, improving healthcare policies, and increasing awareness among people is expected to fuel the segment growth in the region.

Scope of The Report

Report Coverage Details
Market Size in 2021 USD 3.5 billion
Revenue Forecast by 2030 USD 7.3 billion 
Growth rate from 2022 to 2030 CAGR of 8.51%
Base Year 2021
Forecast Period 2022 to 2030
Segmentation Technology, Pathogen, End-User, Region
Companies Covered

F. Hoffmann-La Roche, Ltd., Abbott, BD, Danaher, and Accelerate Diagnostics, Inc.


Key Players

  • F. Hoffmann-La Roche, Ltd.
  • Abbott
  • BD
  • Danaher
  • Accelerate Diagnostics, Inc.

Market Segmentation

  • By Technology
    • Microbiology Culture
    • Immunoassay
    • PCR
    • NGS
    • Mass Spectrometry
    • Rapid & Point of Care
    • Others
  • By Pathogen
    • Drug Resistant Streptococcus Pneumoniae (DRSP)
    • Drug Resistant Campylobacter (DRC)
    • Clostridium Difficile (CD)
    • Methicillin Resistant Staphylococcus Aureus (MRSA)
    • Drug Resistant Neisseria Gonorrhoeae (DRNG) 
    • Drug Resistant Salmonella (DRNTS)
    • Others
  • By End-User
    • Hospitals
    • Diagnostic Laboratories
    • Pharmaceutical & Biotechnology Companies
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Report Detail

Proceed To Buy

USD 3500
USD 7000